Mangoceuticals, Inc. (MGRX) Return on equity 2022–2025
Mangoceuticals, Inc. (MGRX) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-135.8%FY2025 · since FY2022: -325.4% → -135.8%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -135.8% | -73.4 pp |
| FY2024 | -62.4% | +1126.6 pp |
| FY2023 | -1189.1% | -863.7 pp |
| FY2022 | -325.4% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More MGRX financial trends
MGRX RevenueMGRX Net incomeMGRX Net marginMGRX Gross profitMGRX Gross marginMGRX Operating incomeMGRX Operating marginMGRX Operating cash flowMGRX Free cash flowMGRX Capital expendituresMGRX Stock buybacksMGRX Dividends paidMGRX Total assetsMGRX Total liabilitiesMGRX Shareholders’ equityMGRX overview →